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Objective: Clinical tools are needed to identify and target a neuropathic-like phenotype, which may be
associated with central sensitization (CS), in osteoarthritis (OA). The modiﬁed painDETECT questionnaire
(mPD-Q) has face and content validity for identifying neuropathic-like symptoms in knee OA. To further
validate the mPD-Q, this study assessed the unknown relationship between mPD-Q scores and signs of
CS on quantitative sensory testing (QST) in knee OA.
Design: 36 Individuals were recruited with chronic, symptomatic, knee OA without other pain/neuro-
logical conditions. Reference QST data were obtained from 18 controls/32 eligible knees, enabling
identiﬁcation of sensory abnormalities/CS among case knees. A standardized questionnaire assessed
psychological factors (depressive symptoms and pain catastrophizing), and for individual knees, mPD-Q
and pain intensity scores. A standardized/comprehensive QST protocol was conducted for each knee. QST
signs of CS were deﬁned as: mechanical hyperalgesia and/or enhanced temporal summation and/or
allodynia. The relationship between the presence of CS (yes/no) and a pre-selected mPD-Q score (12 or
>12), by knees, was assessed using generalized estimating equations.
Results: Among 57 eligible case knees, 45.6% had 1 sign of CS. Controlling for age, knees with higher
mPD-Q scores (>12.0) had higher odds of having QST signs of CS (adjusted odds ratio (OR) ¼ 5.6; 95%
conﬁdence interval (CI), 1.3e22.9). This relationship was unaffected by controlling for depression and
pain intensity, but was attenuated by pain catastrophizing.
Conclusions: Among painful OA knees, higher mPD-Q scores were associated with greater odds of having
signs of CS. Thus, the mPD-Q may aid the identiﬁcation of CS in people with chronic knee OA.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
There has been an important shift in the classiﬁcation and
treatment of chronic pain disorders, away from a focus on disease
towards identifying and targeting underlying pain mechanisms1.
Cumulative data suggest that, in addition to nociceptive mecha-
nisms, central sensitization (CS) may contribute to chronic pain in a
subset of people with osteoarthritis (OA)2e4. CS may be elicited inJ.R. Hochman, Women’s Col-
01, Toronto, ON, Canada M5S
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s Research Society International. Posteoarthritic joints from chronic nociceptor stimulation leading to
modiﬁcation of central pain transmitting neurons5 or alternatively,
from neuropathic pain mechanisms, e.g., arising from damage to a
nerve innervating an affected joint. Clinically, CS may be associated
with neuropathic pain qualities, e.g., spontaneous electric-shock
like pain6,7, and sensory abnormalities, which can be identiﬁed on
quantitative sensory testing (QST), e.g., mechanical hyperalgesia,
enhanced temporal summation, and allodynia3,8. Psychological and
cognitive factors, e.g., depression and pain catastrophizing, which
are known contributors to the OA pain experience9e11, may further
contribute to the maintenance of CS in OA.
Heterogenous pain mechanisms in OA may explain variable
responses to recommended pain therapies12. Accurate classiﬁ-
cation of OA pain phenotype using clinically feasible tools has
potential to improve pain management. Patient-report questionublished by Elsevier Ltd. All rights reserved.
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symptoms in people with chronic pain13. The PainDETECT, a
patient-report questionnaire, originally developed to identify
neuropathic pain among people with chronic low back pain14,
has now been validated against expert physician-diagnosis of
neuropathic pain in people with a range of chronic pain con-
ditions14.
In prior work, we modiﬁed the PainDETECT (modiﬁed PainDE-
TECT, mPD-Q) for use in older individuals with knee OA15. In 171
individuals with chronic painful knee OA, the mPD-Q was found to
have face and content validity7. Approximately one-quarter of par-
ticipants had symptoms of neuropathic pain (mPD-Q score19/38),
with higher mPD-Q scores signiﬁcantly and independently associ-
ated with greater pain intensity, radiating low back pain, and co-
morbid neurological conditions7. Among those without known
neurological conditions, the proportion with scores 19 was 19%.
Thus, the mPD-Q appears to be a clinically feasible self-report tool
thatmayaid the identiﬁcationofneuropathicpain symptomsamong
adults with knee OA. However, further validation work is needed.
The aim of the current study was to evaluate among individuals
with painful knee OA the relationship between neuropathic
symptoms using the mPD-Q and presence of QST signs of CS,
evaluated using a standardized, comprehensive QST protocol,
controlling for potential confounders (depressive symptoms and
pain catastrophizing). Secondary study objectives were to: assess
the discriminant validity of pre-speciﬁed cut-point scores on the
mPD-Q for identifying those with vs without signs of CS on QST;
and explore the full range of somatosensory abnormalities among
OA study participants.
Patients and methods
Study participants
Symptomatic knee OA participants (cases)
Adults with symptomatic knee OAwere recruited frommultiple
sources, e.g., investigators’ OA cohorts, musculoskeletal (MSK)
clinics, and the community. For each knee, the presence of symp-
tomatic knee OAwas deﬁned as pain, discomfort and/or stiffness in
or around the knee on the majority of days for 3 months, with X-
ray conﬁrmation using Osteoarthritis Research Society Interna-
tional (OARSI) grading16. We aimed to recruit approximately 20
English-speaking individuals, aged 50þ, with knee OA, with similar
representation by age and sex, in each of two groups: mPD-Q score
for the ‘worst’ knee >12 and 12.
The mPD-Q score cut-point of 12, the median value for partici-
pants in our prior knee OA study, was chosen to ensure participants
had a range of mPD-Q scores. In other chronic pain populations,
painDETECT scores19/38 are considered indicative of neuropathic
pain (sensitivity and speciﬁcity 85% and 80%, respectively); scores
13e18 indicate a possible neuropathic component or mixed
neuropathic/nociceptive pain phenotype, while scores 12 suggest
neuropathic pain is unlikely14. From existing evidence in OA, we
hypothesized that a mixed neuropathic/nociceptive symptom
patternwould be more common than a predominately neuropathic
phenotype6,7.
Individuals with self-reported chronic non-OA pain, neurolog-
ical conditions, e.g., peripheral sensory neuropathy, diabetes17, with
daily alcohol use, a history of receiving cancer chemotherapy or
radiation, spine surgery or trauma, or with cognitive impairment
(Short OrientationeMemoryeConcentration Test score <2018),
were excluded. Within individual study participants, only knees for
which there was no history of surgery or trauma were included. An
MSK and neurological examination was conducted by a rheuma-
tologist to conﬁrm eligibility.Controls
Using advertisements and ﬂyers, we aimed to recruit w20
English-speaking controls, without clinically evident OA, with
similar age and sex representation as cases, in order to obtain
reference QST values for knees. In addition to the exclusion criteria
applied to knee OA participants, controls could not have a self-
reported diagnosis of knee arthritis, knee pain over the past 6
months, and/or regular use of analgesic medication. Individual
knees were also excluded at in-person assessment if there was self-
report or examination evidence of sensory abnormalities localized
to the knee or the ipsilateral leg/foot on examination.
Methods
Participants completed a standardized telephone interview
followed 1 week later by an in-person assessment.
Telephone interviews in all participants, obtained data on: soci-
odemographic factors (age, sex, ethnicity, education, marital sta-
tus); body mass index (BMI), based on self-reported height and
weight, and psychological factors (depressed mood, using the
Centre for Epidemiologic Studies Depression Scale [CES-D]19, and
pain catastrophizing, using the Pain Catastrophizing Scale [PCS]20).
To evaluate OA severity, cases additionally completed the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC),
a valid and reliable measure of knee OA pain, stiffness and func-
tional limitations21. Higher scores indicate more severe OA21. The
CES-D is a valid and reliable measure of depressive symptoms in
community dwelling elderly people19,22. A score 16 is considered
indicative of depression22. The PCS is a valid and reliable measure of
pain catastrophizing in older adults with OA20. Higher scores
indicate more pain catastrophizing20.
The in-person assessment was comprised of: a standardized,
interviewer-administered questionnaire; QST; and MSK and
neurological screening examinations. For cases, additional infor-
mation was collected for each eligible knee: the presence/absence
of discomfort; knee pain intensity using the Von Korff Chronic Pain
Grade (CPG) pain intensity subscale23; duration of knee symptoms
(in years); month/year of knee OA physician-diagnosis; and
neuropathic pain symptoms using the mPD-Q. Cases were also
asked to report additional painful joints on a joint homunculus.
Controls were asked about presence/absence of knee pain to
conﬁrm eligibility.
In prior work, with permission, the PainDETECT was modiﬁed to
improve suitability for the knee OA population, while preserving the
scoring scheme15. Modiﬁcations were informed by input frommea-
surement and arthritis experts and individuals with OA. Like the
original painDETECT, themodiﬁed version is comprised of nine items
(seven evaluating pain quality, one evaluating pain pattern, and one
evaluating pain radiation), which contribute to an aggregate score
from 1 to 38. Higher scores indicate more neuropathic-like symp-
toms. The modiﬁed PainDETECT differs from the original measure in
that respondents are asked to reporton their symptoms ‘inoraround’
eachkneeasopposed to their “mainareaofpain”, and, basedon input
from OA patients, spreading up or down from the knee vs radiating
fromtheknee andover thepastmonthvs anunspeciﬁed timeperiod.
In addition, a male ﬁgure was changed to a gender-neutral ﬁgure as
OA affects more women than men. Subsequent pilot testing in 20
individuals with knee OA found the mPD-Q to have improved face
validity and ease of use in patients with knee OA compared with the
PainDETECT. Higher scores on the mPD-Q were associated with
signiﬁcantly higher scores on another neuropathic pain question-
naire, the Self-administered Leeds Assessment of Neuropathic Pain
Symptoms andSigns questionnaire (Spearman r¼ 0.73, P< 0.0001)7.
Following questionnaire completion, the standardized German
Research Network on Neuropathic Pain (DFNS) QST protocol24 was
Table I
Characteristics of OA participants (cases) and controls
Characteristic Cases (n ¼ 36) Controls (n ¼ 18) P values
Sociodemographic factors
Age e mean  SD 60.7  6.8 60.9  6.1 NS
Female e n (%) 30 (83.3) 13 (72.2) NS
Married e n (%) 17 (47.2) 5 (27.8) NS
Caucasian e n (%) 30 (83.3) 14 (77.8) NS
Post-secondary
education e n (%)
29 (80.6) 16 (88.9) NS
BMI* e median (min, max) 28.8 (19.5, 62.3) 25.6 (18.9, 32.4) 0.002
Normal e n (%) 8 (22.2) 8 (44.4)
Overweight e n (%) 15 (41.7) 9 (50.0)
Obese e n (%) 13 (36.1) 1 (5.6)
Psychological factors* e median (min, max)
CES-D score (/60) 6.0 (0.0, 44.0) 1.0 (0.0, 3.0) 0.0002
PCS score (/52) 7.0 (0.0, 51.0) 0.0 (0.0, 0.0) <0.0001
# of tender points (/18) 7.2  5.0 4.5  4.7 NS
* Median (min, max) shown for variables with non-normal distributions;
NS ¼ non-signiﬁcant difference between cases and controls.
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training from a DFNS training center in Mannheim, Germany) on
eligible knees of cases and controls. Using the same equipment as
outlined in the DFNS protocol25, the comprehensive standardized
battery of sensory tests was administered to assess the following
parameters: detection thresholds for cold (cold detection threshold),
warmth (warm detection threshold), light touch (mechanical
detection threshold); pain thresholds in response to cold (cold pain
threshold), heat (heat pain threshold), pinprick (mechanical pain
threshold) and pressure (pressure pain threshold) stimuli; sensi-
tivity to suprathreshold pinprick stimuli (mechanical pain sensi-
tivity); temporal summation in response to repetitive pinprick
stimuli (wind-up ratio); dynamic mechanical allodynia; and number
of paradoxical heat sensations during application of alternating cold
andwarm stimuli (thermal sensory limen). Among individuals with
neuropathic pain conditions, testeretest and inter-rater reliability
has been shown to be high at affected areas for all QST parameters
(r ¼ 0.80e0.93) except wind-up ratio (r ¼ 0.56e0.67) and para-
doxical heat sensations (r ¼ 0.35e0.44)26. For each eligible case
knee, sensory gain (gain of function) and sensory loss (loss of
function) were assessed for all parameters. QST was performed in a
quiet roomwith participants seated comfortably on an examination
bench with legs out-stretched. QST tests were performed at the
antero-medial joint line (the most common site of pain in people
with symptomatic knee OA) aside from vibration threshold, which
was assessed over the tibial tuberosity. As per the DFNS protocol,
participants were asked to close their eyes throughout the QST
procedure to obscure their view of applied stimuli.
Statistical analysis. Descriptive statistics were calculated for all
quantitative and qualitative variables. Cases and controls were
compared for differences in sociodemographics, BMI, and psycho-
logical factorsusing t-testsorWilcoxonranksumtests forcontinuous
variables, and chi-square or Fischer’s exact test for categorical vari-
ables, as appropriate. For both cases and controls, we examined raw
QST values; all but wind-up ratio values were non-normally
distributed and thus logarithmically transformed in subsequent an-
alyses. In the absenceof establishednormative values forQST inolder
adults,we deﬁned thenormal range for eachQST value aswithin two
standard deviations of the mean log transformed QST score for con-
trol knees. Obesity has been associated with both reduced and
increased pain thresholds27. As obesity was more common in cases
than controls, we adjusted our reference QST values by BMI category
(normal,<25, vs overweight or obese,25). Eligible case kneeswere
then classiﬁed as having none, any, and speciﬁc QST abnormalities
and also as having or not having a deﬁned proﬁle of sensory abnor-
malities (mechanical gain or loss, thermal gain or loss, and signs of
CS). Finally, foreacheligible caseknee, CSwasdeﬁnedas thepresence
of one or more of: hyperalgesia to mechanical stimuli (pinprick or
pressure), a shift in stimulus response curve, mechanical allodynia
and/or enhanced temporal summation8,28.
In an exploratory analysis, chi-square testing was used to assess
for a relationship between BMI category (normal vs overweight or
obese) and QST ﬁnding of CS (yes/no) in case knees.
Logistic regression using generalized estimating equations to
control for within individual correlations between case knees was
used to examine the relationship between a knee-based mPD-Q
score suggesting a neuropathic component (score > 12 vs 12) and
the presence of CS (as deﬁned above) adjusted for age (as per DFNS
recommendations). Due to limited sample size, potential con-
founders or mediators of this relationship including depressive
symptoms (CES-D score) and pain catastrophizing (PCS score) were
assessed in individual models including mPD-Q score and age.
Psychological factors may inﬂuence self-report pain ratings/mPD-Q
scores (in part due to negative affect) and potentially alter central
pain processing, contributing to QST signs of CS, independent of OA.Pain intensity was also assessed in the model with mPD-Q score
and age as prior work showed greater pain intensity was signiﬁ-
cantly and independently associated with symptoms of neuro-
pathic pain (mPD-Q score 19). The sensitivity and speciﬁcity of
the mPD-Q cut-point score of 12 (< vs 12;  vs>12) for detecting
signs of CS (yes/no) was calculated. The number of participants
with mPD-Q scores over 19 was too small to assess this additional
cut-point score. All analyses were performed using SAS 9.1.
This study was conducted according to the principles expressed
in theDeclarationofHelsinki. Approvalwasobtainedby the research
ethics boards atWomen’s CollegeHospital and theUniversityHealth
Network. All participants gave written, informed consent.
Results
Characteristics of study participants
Of 199 potential cases screened, 165 (83%) were ineligible for
participation (75 other pain conditions, 17 insufﬁcient knee OA
symptom duration, 26 knee injury or surgery in previous year, 13
conditions associated with neuropathy, 17 other and 17 refused,
leaving 36 case participants). Most cases were female, Caucasian,
had post-secondary education, were overweight or obese, and had
knee OA symptoms of long duration. Five (13.9%) cases had CES-D
scores >16, suggesting depression. Twenty-eight cases (77.8%)
had bilateral knee pain; of these 28, 21 had two eligible knees and
seven had one eligible knee (total of 57 eligible case knees e 28
right and 29 left knees). Mean WOMAC and CPG pain intensity
scores indicated moderate knee symptom severity. At assessment,
the median mPD-Q score for case knees was 9 (range 0e33.0);
mPD-Q scores were >12 for 37% of case knees and 19 for 11% of
case knees. Tables I and II
Of 84 potential controls screened, 62 (73.8%) were ineligible for
participation (two past knee surgery/injury, 30 pain conditions, ﬁve
neuropathic conditions, one regularuseof painmedications, 20ageor
sex category already full, four neuropathy identiﬁed on examination),
and four refused participation, leaving 18 controls with 32 eligible
knees (15 rightand17 left knees). Casesandcontrolswere similarwith
respect to sociodemographics, but compared with the controls, cases
were more likely to be overweight or obese, had more depressive
symptoms and higher pain catastrophizing scores (Table I).
Results of QST
The raw QST parameter values for eligible case and control
knees are shown in Table III. Case knees had higher values than
Table II
Characteristics of knee OA and neuropathic pain symptoms among case knees
Characteristic Case knees (n ¼ 57)
Duration of knee OA symptoms in
years* e median (min, max)
10.0 (0.2, 55.0)
Time since knee OA diagnosis in
years* e median (min, max)
4.0 (0.0, 44.0)
WOMAC scorey e mean (SD)
Pain (/20) 8.2  4.2
Stiffness (/8) 3.5  2.0
Physical function (/68) 27.0  13.3
Total (/96) 38.7  18.5
CPG pain intensity score (/100) e mean (SD) 52.0  19.8
Neuropathic pain symptoms
mPD-Q score* e median (min, max) 9.0 (0.0,33.0)
* Median (min, max) shown for variables with non-normal distributions.
y Variable assessed by participant rather than by knee. CPG ¼ Von Korff Chronic
Pain Grade subscale for pain intensity.
Table IV
Frequency distribution of sensory abnormalities for case knees classiﬁed as gain,
normal or loss of sensory function for each QST parameter (n ¼ 58)
QST parameter Gain* n (%) Normal n (%) Loss* n (%)
Hyperesthesia Normal Hypoesthesia
Cold detection threshold
Right knee 0 (0.0) 23 (82.1) 5 (17.9)
Left knee 0 (0.0) 28 (96.5) 1 (3.5)
Warm detection threshold
Right knee 0 (0.0) 18 (64.3) 10 (35.7)
Left knee 2 (6.9) 17 (58.6) 10 (34.5)
Thermal sensory limen
Right knee 0 (0.0) 21 (75.0) 7 (25.0)
Left knee 1 (3.5) 21 (72.4) 7 (24.1)
Mechanical detection
Right knee 0 (0.0) 17 (60.7) 11 (39.3)
Left knee 2 (6.9) 20 (69.0) 7 (24.1)
Hyperalgesia Normal Hypoalgesia
Cold pain detection threshold
Right knee 0 (0.0) 21 (75.0) 7 (25.0)
Left knee 0 (0.0) 29 (100.0) 0 (0.0)
Heat pain detection threshold
Right knee 1 (3.6) 27 (96.4) 0 (0.0)
Left knee 3 (10.3) 26 (89.7) 0 (0.0)
Mechanical pain threshold
Right knee 1 (3.6) 26 (92.8) 1 (3.6)
Left knee 9 (31.0) 19 (65.5) 1 (3.5)
Stimulus response function
Right knee 5 (17.8) 22 (78.6) 1 (3.6)
Left knee 9 (31.0) 20 (69.0) 0 (0.0)
Temporal summation e wind-up ratio
Right knee 1 (3.7) 22 (81.5) 4 (14.8)
Left knee 0 (0.0) 27 (93.1) 2 (6.9)
Pressure pain threshold
Right knee 3 (11.1) 22 (81.5) 2 (7.4)
Left knee 2 (6.9) 2 (6.9) 25 (86.2)
Note: classiﬁcation for temporal summation calculated on the arithmetic scale not
the logarithmetic scale.
* Deﬁned as >2 standard deviations above or below the mean of controls (after
converting to the logarithmic scale). Classiﬁed as ‘gain’ if corresponded to
either hyperesthesia or hyperalgesia. Classiﬁed as ‘loss’ if corresponded to either
hypoesthesia or hypoalgesia.
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and dynamic mechanical allodynia. Based on the distribution of
values for controls, 44 (77.2%) case knees had at least one sensory
abnormality; 26 knees (45.6%) met criteria for CS.
The frequency of speciﬁc sensory abnormalities for eligible case
knees, classiﬁed as gain, normal or loss of sensory function for each
QST parameter, is shown in Table IV (data shown by right and left
knees). More than one-third (38.6%) of eligible case knees had
thermal hypoesthesia, 31.6% mechanical hypoesthesia, 12.3% ther-
mal hypoalgesia, 7.0% thermal hyperalgesia and 3.5%, thermal hy-
peresthesia. Combined hyperalgesia and hypoesthesiawas found in
13 knees (22.8%): four knees (7.0%) had mechanical hyperalgesia
and mechanical hypoesthesia, while 11 (19.3%) knees had me-
chanical hyperalgesia and thermal hypoesthesia. Thermal hyper-
algesia was not found in combination with either mechanical or
thermal hypoesthesia. Fifteen (26.32%) OA knees had one or more
paradoxical heat sensation compared to 1 (3.1%) of control knees. Of
the knees with1 sign of CS, 21 (36.8%) case knees had mechanical
hyperalgesia, 6 (10.5%) had enhanced temporal summation, and
three (5.3%) had allodynia. Ten participants with two knees
assessed had signs of CS around only one knee, while ﬁve partici-
pants with two knees assessed had signs of CS around both knees.
Inﬂuence of BMI on QST
In an exploratory analysis, we found no relationship between
BMI category and CS (data not shown).Table III
Raw QST data for knees of cases and controls
QST parameter Right knees
Cases (n ¼ 28)
median (95% CI*)
C
m
Cold detection threshold (C) 27.6 (25.7e29.0)
Warm detection threshold (C) 36.7 (35.5e38.8)
Thermal sensory limen (C) 10.4 (8.4e13.7)
Cold pain detection threshold (C) 21.2 (1.5e23.7)
Cold pain intensity (/100) 25.8 (6.7e40.0)
Heat pain detection threshold (C) 42.6 (41.5e44.5)
Heat pain intensity (/100) 33.3 (23.3e56.7)
Mechanical detection threshold (mN) 4.7 (2.8e7.0)
Mechanical pain threshold (mN) 27.1 (16.0e48.5)
Mechanical pain sensitivity rating (0e100) 2.2 (1.2e4.4)
Dynamic mechanical allodynia (pain
rating 0e100)
0.1 (0.1e0.1)
Wind-up ratio (ratio) 0.5 (0.3e0.6)
Pressure pain threshold (kPa) 298.7 (247.0e413.3) 3
Mean pressure pain intensity (/100) 33.3 (18.3e50.0)
* 95% CIs for the medians are distribution-free.Relationship between mPD-Q scores and CS
Controlling for age, knees with mPD-Q scores >12.0 vs 12 had
a signiﬁcantly higher odds of meeting criteria for CS (adjusted odds
ratio (OR) 5.6; 95% conﬁdence interval (CI) 1.3e22.9, P ¼ 0.018).
Additional adjustment for pain intensity (adjusted OR, 95% CI, forLeft knees
ontrols (n ¼ 15)
edian (95% CI*)
Cases (n ¼ 29)
median (95% CI*)
Controls (n ¼ 17)
median (95% CI*)
28.7 (26.6e29.9) 28.3 (27.6e29.2) 28.2 (26.7e29.8)
35.5 (35.0e36.6) 36.1 (35.2e37.5) 35.5 (35.0e36.6)
7.8 (5.6e9.7) 8.6 (7.3e12.0) 8.0 (6.8e10.2)
14.3 (2.3e22.6) 13.6 (5.7e23.5) 14.3 (1.5e22.2)
18.3 (5.0e28.3) 18.3 (10.0e36.7) 17.0 (1.3e23.3)
44.8 (40.0e46.0) 44.9 (43.2e46.9) 45.3 (42.0e46.0)
26.3 (16.7e40.0) 46.7 (15.0e60.0) 25.0 (16.7e38.3)
2.3 (1.6e3.5) 2.6 (1.9e3.7) 2.6 (2.0e3.7)
42.2 (22.6e59.7) 16.0 (11.3e32.0) 42.2 (26.0e55.7)
1.4 (0.9e3.5) 2.3 (1.5e5.7) 1.1 (0.8e2.7)
0.1 (0.1e0.1) 0.1 (0.1e0.1) 0.1 (0.1e0.1)
0.5 (0.3e0.6) 0.5 (0.4e0.5) 0.5 (0.3e0.5)
10.2 (238.3e393.0) 347.3 (316.3e411.7) 341.8 (276.7e407.7)
23.3 (10.0e46.7) 23.3 (13.3e46.7) 21.7 (10.0e43.3)
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depressed mood (adjusted OR for higher vs lower mPD-Q
scores ¼ 6.3, 95% CI 1.4e27.1, P ¼ 0.014), did not attenuate this
relationship. However, adjustment for pain catastrophizing atten-
uated the relationship between mPD-Q scores and CS, which
became non-signiﬁcant (adjusted OR for higher vs lower mPD-Q
scores ¼ 3.71, 95% CI 0.7e20.4, P ¼ 0.13).
Sensitivity and speciﬁcity of the mPD-Q cut-point score of 12
The number of study participants with and without signs of CS
by mPD-Q score category (<12 vs 12 and 12 vs>12) is shown in
Table V with corresponding sensitivity and speciﬁcity values.
Discussion
In adults with chronic, painful knee OA, higher scores for
neuropathic pain-like symptoms, evaluated using a modiﬁed
version of the PainDETECT, the mPD-Q, were associated with a
greater likelihood of having QST signs of CS. Controlling for age,
knees with mPD-Q scores >12 were almost six times more likely
than those with lower scores to have signs of CS.
These ﬁndings provide further support for the validity of the
mPD-Q as a tool to aid in the detection of CS in individuals with
knee OA. Only one other study has examined the relationship be-
tween self-reported neuropathic pain symptomswith signs of CS in
OA. In 20 adults with hip OA awaiting arthroplasty, Gwylim et al.29
examined the relationship between PainDETECT scores and signs of
CS, using an abbreviated version of the DFNS protocol and func-
tional magnetic resonance imaging (fMRI). Participants with high
PainDETECT scores (above the sample median) were more likely to
have signs of CS, e.g., higher ratings of sharpness and greater ce-
rebral activity on fMRI during punctate stimulation29. Together,
these studies suggest that questionnaires have the potential to
assist clinicians and researchers in identifying a neuropathic pain
phenotype in the setting of chronic painful OA, and thus in selection
of pain therapy. For example, higher mPD-Q scores may identify
individuals who could beneﬁt from Duloxetine, a serotonin
norepinephrine re-uptake inhibitor, which is now approved for the
treatment of OA pain. Alternatively, treating concomitant depres-
sion and/or poor sleep with medications that also target neuro-
pathic pain, such as tricyclic antidepressants or alpha2-delta
ligands e.g., pregabalin may reduce the contribution of CS to OA
pain, in particular, in those with higher mPD-Q scores.
Based on the current study, we cannot recommend using a cut-
point score of 12 on the mPD-Q to identify patients with CS; the
sensitivity and speciﬁcity values associated with this cut-point
score were not sufﬁciently robust. However, given the relatively
high frequency of mechanical hyperalgesia in our knee OA cases
(36.8%), and its positive relationship with mPD-Q scores, screening
knee OA patients with both the mPD-Q and punctate testing may
enhance the discriminative validity for identifying patients with CS.
Ongoing research in larger samples is needed to conﬁrm ourTable V
Sensitivity and speciﬁcity associatedwithmPD-Q values<12 vs12 and12 vs>12
in identifying subjects who met criteria for CS
Signs of CS absent Signs of CS present
mPD-Q score <12 22 9
mPD-Q score 12 11 15
Sensitivity 58% Speciﬁcity 71%
mPD-Q score 12 23 13
mPD-Q score >12 8 13
Sensitivity 50% Speciﬁcity 74%ﬁndings, and to elucidate the optimal cut-point score for identi-
fying CS on patient-reported questionnaires, and also the added
beneﬁts of questionnaires in combination with QST.
Our study explicitly assessed for, and examined the effect of,
other factors that have previously been shown to moderate or
mediate the development of CS in individuals with chronic pain.
Speciﬁcally, we examined the inﬂuence of pain intensity, depres-
sive symptoms, and pain catastrophizing on the relationship be-
tween neuropathic-like pain symptoms and signs of CS30,31. Few
studies have adequately considered the inﬂuence of these other
patient factors. We found that neither controlling for pain intensity
nor depressive symptoms impacted the observed relationship be-
tween mPD-Q scores and signs of CS. However, controlling for pain
catastrophizing attenuated the relationship, which became non-
signiﬁcant. Pain catastrophizing has been previously linked to
greater pain severity and lower experimental pain thresholds32.
However, there is a paucity of data on the role of pain catastroph-
izing in the development of CS in OA. Further research is needed to
understand whether this cognitive factor mediates or confounds
the relationship between neuropathic-like symptoms and signs of
CS in people with OA.
Though combinations of symptoms and sensory signs are not
diagnostic of speciﬁc pain mechanisms33, our ﬁndings lend further
support to the hypothesis that CS contributes to the pain experi-
ence in a subset of people with OA2,7. Additionally, the ﬁnding of
both negative and mixed sensory signs in one-ﬁfth of knee OA
participants suggests neuropathic mechanisms may contribute to
pain associated with OA17. Co-existing sensory gain and sensory
loss has been considered a hallmark of neuropathic pain17. In our
study, negative sensory signs were found predominately among
non-nociceptive QST parameters, including thermal and mechani-
cal hypoesthesia, suggesting dysfunction may be occurring along
nerve ﬁbers that detect warmth (c ﬁbers), cold (Ad ﬁbers), and
mechanical sensation (Ab ﬁbers)24.
While nerve damage is not a recognized feature of OA, there
may be sub-clinical damage to small peripheral nerves innervating
OA joints4. Along damaged nerves, increased ectopic activity can
occur and contribute to ongoing pain17. Indeed, some animal OA
models have shown that nerves re-innervating damaged tissues
had proﬁles similar to that seen in nerve-injury models, including
abnormal morphology and an excess of neuropeptides involved in
pain transmission4. Alternatively, Magerl and Treede propose
hypoesthesia may be a sign of pain induced somatosensory plas-
ticity at the spinal cord level rather than nerve damage34. Experi-
ments using the capsaicin model of hyperalgesia based on CS have
shown intra-cutaneous injection of capsaicin leads to both me-
chanical hyperalgesia and tactile hypoesthesia that can outlast the
inciting stimulus34. Further study is needed to evaluate the full
range of somatosensory abnormalities in the knee OA population
and elucidate the causative mechanisms.
Findings from past QST studies3 are difﬁcult to compare to our
study’s results due to diversity in QST protocols and the common
practice of comparing somatosensory abnormalities at the group
level rather than amongst individuals with OA. However, our
ﬁndings are consistent with a recent study that utilized part of the
DFNS protocol to assess somatosensory abnormalities in knee OA35.
Von frey hairs, a digital pressure algometer, and a thermotest MSA
were used to assess light touch, pressure pain, thermal sensation,
and thermal pain thresholds amongst 150 individuals with
advanced knee OA compared to healthy controls. Among study
participants, 71% had 1 sensory abnormality (mechanical hyper-
algesia in the form of pressure hyperalgesia, tactile and/or thermal
hypoesthesia). This study found a higher prevalence of pressure
hyperalgesia compared to our study (31% vs 9%)35. The frequency of
individual sensory abnormalities may be expected to vary among
J.R. Hochman et al. / Osteoarthritis and Cartilage 21 (2013) 1236e1242 1241different patient groups with heterogeneity in OA cases, e.g., dif-
ferences in symptom and disease severity and other factors that
may inﬂuence sensory ﬁndings including psychological factors, co-
morbid conditions, and analgesic use. Alternatively, differences in
control participants between the two studies may have inﬂuenced
somatosensory ﬁndings. Further study is needed to elucidate fac-
tors that inﬂuence speciﬁc somatosensory abnormalities among
individuals with OA. In addition, normative data from larger control
groups would aid the assessment of sensory abnormalities among
individuals with OA and facilitate comparisons across studies.
Strengths of our study include use of the validated, standardized,
comprehensive DFNS QST protocol, which enables identiﬁcation of
sensory abnormalities within individuals (rather than comparing
group means), exclusion of individuals with other chronic pain/
neurological disorders, control for additional potential confounding
variables, such as psychosocial factors, and the use of age- and sex-
matched controls to deﬁne normative QST values. However, there
are also some study limitations. First, there is currently no gold
standard for the diagnosis or evaluation of CS28. For this reason, we
deﬁned CS based on QST ﬁndings that have been linked with CS in
human experimental studies28. Second, although we attempted to
reduce the potential for confounding through our inclusion and
exclusion criteria, there always remains the possibility that un-
measured confounders explain the documented relationship be-
tween neuropathic-like symptoms and signs of CS. Third, due to the
comprehensive nature of our assessments, we had to limit the
number of study participants and rely on a small group of controls to
obtain reference QST values. It is possible that sub-clinical sensory
abnormalities went undetected in control knees, skewing reference
data. Research in larger samples is needed to conﬁrm this study’s
ﬁndings and establish knee-speciﬁc reference QST values.
Conclusion
Using QST, a broad range of somatosensory abnormalities was
identiﬁed in individuals with chronic, painful knee OA, supporting
the role of non-nociceptive mechanisms in this common condition.
Further, 45% of symptomatic OA knees had ﬁndings consistent with
CS. Controlling for age, those knees with higher mPD-Q scores were
more likely to have QST signs of CS, suggesting the mPD-Q may aid
the identiﬁcation of CS in adults with knee OA. Additional studies
are needed to conﬁrm our ﬁndings before the mPD-Q can be rec-
ommended for use in clinical practice.
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